<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04583592</url>
  </required_header>
  <id_info>
    <org_study_id>NI03-CV19-001</org_study_id>
    <nct_id>NCT04583592</nct_id>
  </id_info>
  <brief_title>Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sagent Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sagent Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study of camostat mesilate in&#xD;
      ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized in a 2:1 ratio of camostat:placebo. Approximately 300&#xD;
      participants are planned to be enrolled (200 participants to camostat mesilate and 100&#xD;
      participants to placebo). Participants will be treated with camostat mesilate 200 mg or&#xD;
      placebo drug orally 4 times a day for 14 days, and receive local standard of care (SOC) in&#xD;
      addition to study drug. Participants will be followed until Day 28. Participants will be seen&#xD;
      in the clinic for assessments, blood draws, and mid-turbinate nasal samples on Screening/Day&#xD;
      1, Day 7, Day 15 and early termination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression at Day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival Rate</measure>
    <time_frame>Up to Day 15 and Day 28</time_frame>
    <description>The overall survival rate (the number of randomized participants who survive up to Day 15 and Day 28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Fever Resolution</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time (in days) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 3 days only assessed in participants who experienced a fever within 1 day of enrollment up to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of Viral Shedding</measure>
    <time_frame>Day 1, Day 7 and Day 15</time_frame>
    <description>Number of participants with no viral shedding (yes/no) using reverse transcriptase-polymerase chain reaction (RT-PCR) at Day 7, Day 15, and at early termination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events and Serious Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants with Adverse events (AEs) and Serious adverse events (SAEs) of any grade from randomization up to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Rate of Grade 3 and 4 Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Cumulative number of participants with grade 3 and 4 AEs from randomization up to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Discontinuation</measure>
    <time_frame>28 days</time_frame>
    <description>Number of participants that discontinued from study due to an AE/SAE (discontinued participants will be followed up to Day 28).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Platelet Count</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical Laboratory Value of Platelet Count at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Potassium Level</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical laboratory value of Potassium Levels at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Aspartate Aminotransferase (AST)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical laboratory values of Aspartate Aminotransferase (AST) at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Alanine Aminotransferase (ALT)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical laboratory value of Alanine Aminotransferase (ALT) at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Alkaline Phosphatase (ALP)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical laboratory value of Alkaline Phosphatase (ALP) at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>Clinical laboratory value of Gamma-Glutamyl Transferase (GGT) at Day 1 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Heart Rate</measure>
    <time_frame>Day 1, Day 7 and Day 15</time_frame>
    <description>Heart rate at Day 1, Day 7 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Blood Pressure</measure>
    <time_frame>Day 1, Day 7 and Day 15</time_frame>
    <description>Blood pressure (BP) at Day 1, Day 7 and Day 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)</measure>
    <time_frame>Day 1, Day 7 and Day 15</time_frame>
    <description>Peripheral Capillary Oxygen Saturation (SpO2) at Day 1, Day 7 and Day 15</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">295</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Camostat Mesilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo for 14 days in addition to standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat Mesilate</intervention_name>
    <description>Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
    <arm_group_label>Camostat Mesilate</arm_group_label>
    <other_name>Camostat Mesylate</other_name>
    <other_name>Foipan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults willing and able to provide informed consent before performing study procedures&#xD;
&#xD;
          2. Adults ≥18 years of age at time of informed consent&#xD;
&#xD;
          3. Participants must have written notification of laboratory confirmed COVID-19 infection&#xD;
             performed prior to screening, at a local laboratory by RT-PCR or other commercial or&#xD;
             public health assay in any specimen; and participants must be randomized within 72&#xD;
             hours of receiving the above notification of laboratory confirmed COVID-19&#xD;
&#xD;
          4. Have a mild or moderate form of COVID-19 defined as SpO2 &gt; 94% at screening&#xD;
&#xD;
          5. Participants must have at least 1 of the following risk factors for severe illness&#xD;
&#xD;
               1. Aged 65 years or older&#xD;
&#xD;
               2. Hypertension&#xD;
&#xD;
               3. Diabetes mellitus&#xD;
&#xD;
               4. Chronic lung disease including asthma, chronic obstructive pulmonary disease&#xD;
                  (COPD), and interstitial lung disease (eg, idiopathic pulmonary fibrosis)&#xD;
&#xD;
               5. Chronic cardiac conditions, including coronary artery disease (CAD), heart&#xD;
                  failure, congenital heart disease, cardiomyopathy&#xD;
&#xD;
               6. Severe obesity (body mass index [BMI] ≥ 40 kg/m^2)&#xD;
&#xD;
               7. Chronic liver disease, including cirrhosis&#xD;
&#xD;
          6. Must agree not to enroll in another study of an investigational agent or take any&#xD;
             other drug that has been granted Emergency Use Authorization prior to completion of&#xD;
             Day 28&#xD;
&#xD;
          7. If women of childbearing potential (WOCBP) or men whose sexual partners are WOCBP,&#xD;
             must be able and willing to use at least 1 highly effective method of contraception&#xD;
             during the study and for 90 days after receiving the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physician makes a decision that trial involvement is not in participants' best&#xD;
             interest, or has any condition that does not allow the protocol to be followed safely&#xD;
&#xD;
          2. Known severe liver disease (eg, Child Pugh score &gt; 12, AST &gt;5 times upper limit)&#xD;
&#xD;
          3. SaO2/SPO2 ≤94% on room air condition, or the Pa02/Fi02 ratio &lt; 300 mgHg&#xD;
&#xD;
          4. Known allergic reaction to camostat mesilate or one of its excipients&#xD;
&#xD;
          5. Known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73&#xD;
             m^2) or receiving dialysis&#xD;
&#xD;
          6. Pregnant or breastfeeding, or positive pregnancy test in a predose examination&#xD;
&#xD;
          7. Receipt of any experimental treatment for COVID-19, including agents with demonstrated&#xD;
             or possible direct acting antiviral activity, including, but not limited to,&#xD;
             remdesivir, hydroxychloroquine, lopinavir/ritonavir, tocilizumab, or ivermectin,&#xD;
             within the 30 days prior to the time of the screening evaluation. No off label use of&#xD;
             a drug for COVID 19 is allowed.&#xD;
&#xD;
          8. History of human immunodeficiency virus infection on highly active antiretroviral&#xD;
             therapy (HAART)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Palmtree Clinical Research, Inc. (Site 125)</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Healthcare, LLC (Site 124)</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Brandon, LLC (Site 123)</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliable Clinical Research, LLC (Site 100)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A+ Research (Site 112)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NextPhase Research Alliance at CANO HEALTH (Site 107)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ezy Medical Research (Site 106)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eminat LLC (Site 117)</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Invictus Clinical Research Group, LLC (Site 101)</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionaries Clinical Research, LLC (Site 121)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Care Research (Site 114)</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar Crosse Research Center (Site 122)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Site 110)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakland Medical Research Center (Site 108)</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cary Research Group (Site 111)</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onsite Solutions (Site 118)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research (Site 109)</name>
      <address>
        <city>Springboro</city>
        <state>Ohio</state>
        <zip>45066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Institute of Clinical Research, Inc.(Site 105)</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Trials (Site 104)</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Next Innovative Clinical Research (Site 115)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rio Grand Valley Clinical Research Institute (Site 120)</name>
      <address>
        <city>Pharr</city>
        <state>Texas</state>
        <zip>78577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2022</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2020</study_first_posted>
  <results_first_submitted>December 14, 2021</results_first_submitted>
  <results_first_submitted_qc>January 13, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2022</results_first_posted>
  <last_update_submitted>January 13, 2022</last_update_submitted>
  <last_update_submitted_qc>January 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabexate</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04583592/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 31, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04583592/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was performed between November 09, 2020 to March, 30 2021. Subjects were recruited from ~25 sites across United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Camostat Mesilate</title>
          <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="194"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat population includes all subjects who were randomized. [Note: Subjects may have more than one risk factor upon entry into study.]</population>
      <group_list>
        <group group_id="B1">
          <title>Camostat Mesilate</title>
          <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="194"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or = 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>The Intent-to-Treat population includes all subjects who were randomized.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease Progression at Day 28</title>
        <description>Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.</description>
        <time_frame>28 days</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression at Day 28</title>
          <description>Disease progression will be defined as the number of participants requiring hospitalization (including emergency room visit) or who die due to any cause within 28 days of randomization.</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.787</p_value>
            <p_value_desc>&lt;0.05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival Rate</title>
        <description>The overall survival rate (the number of randomized participants who survive up to Day 15 and Day 28).</description>
        <time_frame>Up to Day 15 and Day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival Rate</title>
          <description>The overall survival rate (the number of randomized participants who survive up to Day 15 and Day 28).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Survival Status at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survival Status at Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fever Resolution</title>
        <description>Time (in days) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 3 days only assessed in participants who experienced a fever within 1 day of enrollment up to Day 28.</description>
        <time_frame>Up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fever Resolution</title>
          <description>Time (in days) from initiation of study treatment until normalization of fever (≤ 37.2 °C oral or tympanic) and sustained for at least 3 days only assessed in participants who experienced a fever within 1 day of enrollment up to Day 28.</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="1" lower_limit="1.0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of Viral Shedding</title>
        <description>Number of participants with no viral shedding (yes/no) using reverse transcriptase-polymerase chain reaction (RT-PCR) at Day 7, Day 15, and at early termination.</description>
        <time_frame>Day 1, Day 7 and Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Resolution of Viral Shedding</title>
          <description>Number of participants with no viral shedding (yes/no) using reverse transcriptase-polymerase chain reaction (RT-PCR) at Day 7, Day 15, and at early termination.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No Viral Shedding at Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Viral Shedding at Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Viral Shedding at Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Adverse Events and Serious Adverse Events</title>
        <description>Number of participants with Adverse events (AEs) and Serious adverse events (SAEs) of any grade from randomization up to Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Adverse Events and Serious Adverse Events</title>
          <description>Number of participants with Adverse events (AEs) and Serious adverse events (SAEs) of any grade from randomization up to Day 28.</description>
          <population>A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Rate of Grade 3 and 4 Adverse Events</title>
        <description>Cumulative number of participants with grade 3 and 4 AEs from randomization up to Day 28.</description>
        <time_frame>28 days</time_frame>
        <population>A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Rate of Grade 3 and 4 Adverse Events</title>
          <description>Cumulative number of participants with grade 3 and 4 AEs from randomization up to Day 28.</description>
          <population>A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Discontinuation</title>
        <description>Number of participants that discontinued from study due to an AE/SAE (discontinued participants will be followed up to Day 28).</description>
        <time_frame>28 days</time_frame>
        <population>The Intent-to-Treat (ITT) population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Discontinuation</title>
          <description>Number of participants that discontinued from study due to an AE/SAE (discontinued participants will be followed up to Day 28).</description>
          <population>The Intent-to-Treat (ITT) population includes all subjects who were randomized.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Platelet Count</title>
        <description>Clinical Laboratory Value of Platelet Count at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>The Intent-to Treat Population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Platelet Count</title>
          <description>Clinical Laboratory Value of Platelet Count at Day 1 and Day 15</description>
          <population>The Intent-to Treat Population includes all subjects who were randomized.</population>
          <units>10^9 platelets/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243" spread="71.69"/>
                    <measurement group_id="O2" value="252.1" spread="80.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Platelet Count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.3" spread="86.66"/>
                    <measurement group_id="O2" value="281.5" spread="83.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Potassium Level</title>
        <description>Clinical laboratory value of Potassium Levels at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Potassium Level</title>
          <description>Clinical laboratory value of Potassium Levels at Day 1 and Day 15</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 Potassium Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="0.397"/>
                    <measurement group_id="O2" value="4.23" spread="0.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 Potassium Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.363"/>
                    <measurement group_id="O2" value="4.29" spread="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Aspartate Aminotransferase (AST)</title>
        <description>Clinical laboratory values of Aspartate Aminotransferase (AST) at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Aspartate Aminotransferase (AST)</title>
          <description>Clinical laboratory values of Aspartate Aminotransferase (AST) at Day 1 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6" spread="14.71"/>
                    <measurement group_id="O2" value="25.3" spread="12.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="10.18"/>
                    <measurement group_id="O2" value="21.8" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Alanine Aminotransferase (ALT)</title>
        <description>Clinical laboratory value of Alanine Aminotransferase (ALT) at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Alanine Aminotransferase (ALT)</title>
          <description>Clinical laboratory value of Alanine Aminotransferase (ALT) at Day 1 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="27.58"/>
                    <measurement group_id="O2" value="29.0" spread="17.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="20.1"/>
                    <measurement group_id="O2" value="27.9" spread="22.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Alkaline Phosphatase (ALP)</title>
        <description>Clinical laboratory value of Alkaline Phosphatase (ALP) at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Alkaline Phosphatase (ALP)</title>
          <description>Clinical laboratory value of Alkaline Phosphatase (ALP) at Day 1 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="24.44"/>
                    <measurement group_id="O2" value="80.5" spread="25.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="27.60"/>
                    <measurement group_id="O2" value="78.6" spread="24.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)</title>
        <description>Clinical laboratory value of Gamma-Glutamyl Transferase (GGT) at Day 1 and Day 15</description>
        <time_frame>Day 1 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)</title>
          <description>Clinical laboratory value of Gamma-Glutamyl Transferase (GGT) at Day 1 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.5" spread="25.61"/>
                    <measurement group_id="O2" value="33.4" spread="29.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="30.50"/>
                    <measurement group_id="O2" value="31.1" spread="20.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Heart Rate</title>
        <description>Heart rate at Day 1, Day 7 and Day 15</description>
        <time_frame>Day 1, Day 7 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Heart Rate</title>
          <description>Heart rate at Day 1, Day 7 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>Beats/Minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="10.25"/>
                    <measurement group_id="O2" value="80.1" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="10.07"/>
                    <measurement group_id="O2" value="80.5" spread="9.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" spread="10.16"/>
                    <measurement group_id="O2" value="79.2" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Blood Pressure</title>
        <description>Blood pressure (BP) at Day 1, Day 7 and Day 15</description>
        <time_frame>Day 1, Day 7 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Blood Pressure</title>
          <description>Blood pressure (BP) at Day 1, Day 7 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.7" spread="13.87"/>
                    <measurement group_id="O2" value="129.6" spread="13.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.2" spread="16.61"/>
                    <measurement group_id="O2" value="129.2" spread="15.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.1" spread="16.61"/>
                    <measurement group_id="O2" value="129.2" spread="15.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.7" spread="8.9"/>
                    <measurement group_id="O2" value="80.8" spread="7.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" spread="9.34"/>
                    <measurement group_id="O2" value="80.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.9" spread="8.72"/>
                    <measurement group_id="O2" value="81.3" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)</title>
        <description>Peripheral Capillary Oxygen Saturation (SpO2) at Day 1, Day 7 and Day 15</description>
        <time_frame>Day 1, Day 7 and Day 15</time_frame>
        <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Camostat Mesilate</title>
            <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)</title>
          <description>Peripheral Capillary Oxygen Saturation (SpO2) at Day 1, Day 7 and Day 15</description>
          <population>The Intent-to-Treat population includes all subjects who were randomized.</population>
          <units>Percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SpO2 Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" spread="1.33"/>
                    <measurement group_id="O2" value="97.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SpO2 Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" spread="1.78"/>
                    <measurement group_id="O2" value="97.3" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SpO2 Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" spread="1.46"/>
                    <measurement group_id="O2" value="97.5" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 Days</time_frame>
      <desc>A total of 295 subjects were randomized (2:1) to receive a 2-week course of Camostat (n=194) or placebo (n=101) One participant randomized to the placebo group decided to withdraw before taking the first dose of study drug, and one subject randomized to the placebo group was erroneously given Camostat mesilate (As Treated Population: Camostat mesilate, n=195 and placebo, n=99).</desc>
      <group_list>
        <group group_id="E1">
          <title>Camostat Mesilate</title>
          <description>Participants will receive camostat mesilate for 14 days in addition to standard of care treatment.&#xD;
Camostat Mesilate: Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive placebo for 14 days in addition to standard of care treatment.&#xD;
Placebo: Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Corneal abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oxygen Saturation Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased apetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aguesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cynthia Tinkoff, Pharm.D. Manager, Medical Affairs</name_or_title>
      <organization>Sagent Pharmaceuticals, Inc.</organization>
      <phone>847-908-6913</phone>
      <email>ctinkoff@sagentpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

